Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise in blocking kaposi sarcoma growth

NCT ID NCT02799485

First seen Jun 05, 2026 · Last updated Jun 19, 2026 · Updated 3 times

Summary

This study tested a drug called sEphB4-HSA in 23 people with Kaposi sarcoma, a type of skin cancer. The drug works by stopping blood vessels from feeding the cancer and may also slow cancer cell growth. The goal was to see how many patients responded to treatment and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SKIN KAPOSI SARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Grady Health System

    Atlanta, Georgia, 30303, United States

  • John H. Stroger Jr., Hospital of Cook County

    Chicago, Illinois, 60612, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21205, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • UCLA CARE Center

    Los Angeles, California, 90025, United States

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • Virginia Mason Medical Center

    Seattle, Washington, 98101, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

The condition(s) this trial relates to.

Kaposi's sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.